- Home
- LNTH vs NCLH Comparison
LNTH vs NCLH Comparison
Compare LNTH & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNTH
- NCLH
- Stock Information
- Founded
- LNTH 1956
- NCLH 1966
- Country
- LNTH United States
- NCLH United States
- Employees
- LNTH N/A
- NCLH N/A
- Industry
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NCLH Marine Transportation
- Sector
- LNTH Health Care
- NCLH Consumer Discretionary
- Exchange
- LNTH Nasdaq
- NCLH Nasdaq
- Market Cap
- LNTH 3.6B
- NCLH 11.5B
- IPO Year
- LNTH 2015
- NCLH 2013
- Fundamental
- Price
- LNTH $50.84
- NCLH $25.40
- Analyst Decision
- LNTH Strong Buy
- NCLH Buy
- Analyst Count
- LNTH 6
- NCLH 19
- Target Price
- LNTH $85.50
- NCLH $28.33
- AVG Volume (30 Days)
- LNTH 1.5M
- NCLH 16.7M
- Earning Date
- LNTH 11-05-2025
- NCLH 10-30-2025
- Dividend Yield
- LNTH N/A
- NCLH N/A
- EPS Growth
- LNTH N/A
- NCLH 61.59
- EPS
- LNTH 3.77
- NCLH 1.54
- Revenue
- LNTH $1,520,653,000.00
- NCLH $9,560,994,000.00
- Revenue This Year
- LNTH N/A
- NCLH $8.19
- Revenue Next Year
- LNTH $3.24
- NCLH $10.51
- P/E Ratio
- LNTH $13.47
- NCLH $16.55
- Revenue Growth
- LNTH 5.75
- NCLH 5.22
- 52 Week Low
- LNTH $47.25
- NCLH $14.21
- 52 Week High
- LNTH $118.21
- NCLH $29.29
- Technical
- Relative Strength Index (RSI)
- LNTH 35.30
- NCLH 52.73
- Support Level
- LNTH $51.94
- NCLH $25.06
- Resistance Level
- LNTH $55.24
- NCLH $27.18
- Average True Range (ATR)
- LNTH 1.83
- NCLH 0.91
- MACD
- LNTH 0.22
- NCLH -0.03
- Stochastic Oscillator
- LNTH 5.04
- NCLH 44.89
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.